vs
Side-by-side financial comparison of Good Times Restaurants Inc. (GTIM) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
Good Times Restaurants Inc. is the larger business by last-quarter revenue ($32.7M vs $23.0M, roughly 1.4× Intellia Therapeutics, Inc.). Good Times Restaurants Inc. runs the higher net margin — 0.6% vs -416.2%, a 416.7% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs -10.0%). Good Times Restaurants Inc. produced more free cash flow last quarter ($1.2M vs $-69.4M). Over the past eight quarters, Good Times Restaurants Inc.'s revenue compounded faster (-0.7% CAGR vs -10.8%).
Good Times is a Golden, Colorado–based fast-food restaurant specializing in premium burgers and frozen custard. As of July 2023, the chain operates 31 locations, down from 38 in 2015.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
GTIM vs NTLA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $32.7M | $23.0M |
| Net Profit | $181.0K | $-95.8M |
| Gross Margin | — | — |
| Operating Margin | 0.9% | -428.9% |
| Net Margin | 0.6% | -416.2% |
| Revenue YoY | -10.0% | 78.8% |
| Net Profit YoY | 10.4% | 25.7% |
| EPS (diluted) | $0.02 | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $32.7M | $23.0M | ||
| Q3 25 | $37.0M | $13.8M | ||
| Q2 25 | $34.3M | $14.2M | ||
| Q1 25 | — | $16.6M | ||
| Q4 24 | $36.3M | $12.9M | ||
| Q3 24 | $35.8M | $9.1M | ||
| Q2 24 | $38.0M | $7.0M | ||
| Q1 24 | $35.4M | $28.9M |
| Q4 25 | $181.0K | $-95.8M | ||
| Q3 25 | $1.5M | $-101.3M | ||
| Q2 25 | $-624.0K | $-101.3M | ||
| Q1 25 | — | $-114.3M | ||
| Q4 24 | $164.0K | $-128.9M | ||
| Q3 24 | $230.0K | $-135.7M | ||
| Q2 24 | $1.3M | $-147.0M | ||
| Q1 24 | $618.0K | $-107.4M |
| Q4 25 | 0.9% | -428.9% | ||
| Q3 25 | 3.3% | -808.9% | ||
| Q2 25 | -1.5% | -772.2% | ||
| Q1 25 | — | -726.6% | ||
| Q4 24 | 0.2% | -1059.9% | ||
| Q3 24 | -0.3% | -1589.0% | ||
| Q2 24 | 3.2% | -1998.6% | ||
| Q1 24 | 1.8% | -394.0% |
| Q4 25 | 0.6% | -416.2% | ||
| Q3 25 | 4.0% | -735.2% | ||
| Q2 25 | -1.8% | -710.8% | ||
| Q1 25 | — | -687.6% | ||
| Q4 24 | 0.5% | -1001.2% | ||
| Q3 24 | 0.6% | -1489.5% | ||
| Q2 24 | 3.5% | -2112.6% | ||
| Q1 24 | 1.7% | -371.3% |
| Q4 25 | $0.02 | $-0.81 | ||
| Q3 25 | $0.14 | $-0.92 | ||
| Q2 25 | $-0.06 | $-0.98 | ||
| Q1 25 | — | $-1.10 | ||
| Q4 24 | $0.02 | $-1.27 | ||
| Q3 24 | $0.01 | $-1.34 | ||
| Q2 24 | $0.12 | $-1.52 | ||
| Q1 24 | $0.06 | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $449.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $33.2M | $671.4M |
| Total Assets | $82.5M | $842.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $449.9M | ||
| Q3 25 | — | $511.0M | ||
| Q2 25 | $2.7M | $459.7M | ||
| Q1 25 | — | $503.7M | ||
| Q4 24 | $3.0M | $601.5M | ||
| Q3 24 | $3.9M | $658.1M | ||
| Q2 24 | — | $691.1M | ||
| Q1 24 | $4.0M | $791.3M |
| Q4 25 | $33.2M | $671.4M | ||
| Q3 25 | $33.1M | $748.4M | ||
| Q2 25 | $31.6M | $715.3M | ||
| Q1 25 | — | $779.9M | ||
| Q4 24 | $32.4M | $872.0M | ||
| Q3 24 | $32.4M | $962.6M | ||
| Q2 24 | $32.3M | $971.1M | ||
| Q1 24 | $31.6M | $1.0B |
| Q4 25 | $82.5M | $842.1M | ||
| Q3 25 | $85.8M | $925.3M | ||
| Q2 25 | $86.9M | $898.9M | ||
| Q1 25 | — | $986.2M | ||
| Q4 24 | $89.5M | $1.2B | ||
| Q3 24 | $87.1M | $1.2B | ||
| Q2 24 | $90.1M | $1.2B | ||
| Q1 24 | $89.0M | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.4M | $-69.3M |
| Free Cash FlowOCF − Capex | $1.2M | $-69.4M |
| FCF MarginFCF / Revenue | 3.8% | -301.6% |
| Capex IntensityCapex / Revenue | 0.6% | 0.5% |
| Cash ConversionOCF / Net Profit | 7.85× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-72.0K | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.4M | $-69.3M | ||
| Q3 25 | $1.3M | $-76.9M | ||
| Q2 25 | $714.0K | $-99.6M | ||
| Q1 25 | — | $-148.9M | ||
| Q4 24 | $-518.0K | $-85.2M | ||
| Q3 24 | $394.0K | $-84.8M | ||
| Q2 24 | $3.2M | $-58.2M | ||
| Q1 24 | $1.8M | $-120.7M |
| Q4 25 | $1.2M | $-69.4M | ||
| Q3 25 | $735.0K | $-76.9M | ||
| Q2 25 | $-105.0K | $-99.9M | ||
| Q1 25 | — | $-149.7M | ||
| Q4 24 | $-1.9M | $-86.2M | ||
| Q3 24 | $-466.0K | $-86.1M | ||
| Q2 24 | $2.0M | $-59.2M | ||
| Q1 24 | $1.2M | $-123.2M |
| Q4 25 | 3.8% | -301.6% | ||
| Q3 25 | 2.0% | -558.2% | ||
| Q2 25 | -0.3% | -701.0% | ||
| Q1 25 | — | -900.1% | ||
| Q4 24 | -5.3% | -669.4% | ||
| Q3 24 | -1.3% | -945.2% | ||
| Q2 24 | 5.3% | -850.9% | ||
| Q1 24 | 3.2% | -425.7% |
| Q4 25 | 0.6% | 0.5% | ||
| Q3 25 | 1.4% | 0.2% | ||
| Q2 25 | 2.4% | 1.7% | ||
| Q1 25 | — | 4.4% | ||
| Q4 24 | 3.9% | 7.6% | ||
| Q3 24 | 2.4% | 14.0% | ||
| Q2 24 | 3.2% | 14.5% | ||
| Q1 24 | 1.7% | 8.7% |
| Q4 25 | 7.85× | — | ||
| Q3 25 | 0.85× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -3.16× | — | ||
| Q3 24 | 1.71× | — | ||
| Q2 24 | 2.44× | — | ||
| Q1 24 | 2.86× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GTIM
Segment breakdown not available.
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
